## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.5% below STRENGTH zone (3.0-6.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($250.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Community Health Systems offloads ambulatory business to Labcorp for $194M**
- Source: The Business Journals | 20251203T215214 | Somewhat-Bullish | Relevance: 100%
- Community Health Systems has completed the sale of some of its ambulatory assets to Labcorp for $194 million. This article briefly explains what assets were sold and how this transaction fits into the company's broader strategy.

**2. Labcorp (LH) director reports grant of 136 Restricted Stock Units vesting Dec. 2026**
- Source: Stock Titan | 20251203T133500 | Neutral | Relevance: 100%
- Labcorp Holdings Inc. director Victor Bulto Carulla reported the grant of 136 Restricted Stock Units (RSUs) on December 1, 2025. These RSUs represent the right to receive one share of Labcorp common stock each and are scheduled to vest fully on December 1, 2026. This transaction is a routine disclosure of director equity compensation and not an open-market purchase or sale.

**3. CHS completes $194 million sale of lab services to Labcorp By Investing.com**
- Source: Investing.com South Africa | 20251202T232600 | Somewhat-Bullish | Relevance: 100%
- Community Health Systems (NYSE:CYH) has completed the sale of select ambulatory outreach laboratory services to Labcorp (NYSE:LH) for approximately $194 million in cash. This strategic move allows CHS to focus on core services and follows other recent announcements including strong Q3 2025 earnings, surpassing revenue expectations, and plans to sell several hospitals. Truist Securities raised its price target for CHS to $4.50, maintaining a Hold rating due to the positive financial performance and strategic actions.

**4. CHS completes $194 million sale of lab services to Labcorp By Investing.com**
- Source: Investing.com UK | 20251202T212600 | Bullish | Relevance: 100%
- Community Health Systems (NYSE:CYH) has completed the sale of select ambulatory outreach laboratory services to Labcorp (NYSE:LH) for approximately $194 million in cash. This strategic move allows CHS to focus on core services while expanding Labcorp's access to laboratory services across 13 states. The transaction follows recent positive financial performance for CHS, including surpassing Q3 2025 revenue expectations and a raised price target from Truist Securities.

**5. Labcorp (NYSE: LH) closes $194M purchase of CHS outreach lab assets in 13 states**
- Source: Stock Titan | 20251202T211500 | Somewhat-Bullish | Relevance: 100%
- Community Health Systems, Inc. (NYSE: CYH) announced the completion of the sale of select ambulatory outreach laboratory service assets to Labcorp (NYSE: LH) for approximately $194 million cash. This transaction involves CHS-affiliated health systems in 13 states and aims to provide broader access to Labcorp's comprehensive testing and laboratory services. Both companies emphasize improved patient experience and access to high-quality healthcare services as key benefits of this strategic move.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | JP Morgan | $317 | $291 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 14.9x stretched relative to 7% growth. Analyst sentiment positive (1 raises, avg +9%). Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.1B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 14.9 |
| Current P/E | 16.0 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.0% to -3.5% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). MACD histogram positive (0.51), confirming momentum. RSI neutral at 44. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.55% (CS: 14) | Weak |
| RSI_14 | 44.3 | Neutral |
| MACD Histogram | 0.51 | Bullish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.968x | Below |
| vs SMA200 | 1.017x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $261.48
- **Stop Loss:** $250.00 (4.4% risk)
- **Target:** $272.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 43
- **Position Value:** $11,243.64
- **Portfolio %:** 11.24%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*